<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431440</url>
  </required_header>
  <id_info>
    <org_study_id>XXXXX</org_study_id>
    <nct_id>NCT04431440</nct_id>
  </id_info>
  <brief_title>Silver Nanoparticles in Multidrug Resistant Bacteria</brief_title>
  <official_title>Bactericidal Effect of Silver Nanoparticles on Methecillin and Vancomycin Resistant Staphylococcus. Aureus (MRSA) Isolated From Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, silver nanoparticles (AgNPs) have been widely used in various applications as&#xD;
      antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery&#xD;
      systems for the treatment of various diseases. The present study investigated the&#xD;
      bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and&#xD;
      Vancomycin resistant Staph aureus (VRSA)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">October 13, 2020</completion_date>
  <primary_completion_date type="Actual">October 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bactericidal effect of silver nanoparticles on multidrug resistant bacteria</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Multidrug Resistent Bacteria</condition>
  <arm_group>
    <arm_group_label>Methicillin resistant staphylococcus aureus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vancomycin resistent staphylococcus aureus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>silver nanoparticles</intervention_name>
    <description>effect silver nanoparticles will be examined on multidrug resistant bacteria</description>
    <arm_group_label>Methicillin resistant staphylococcus aureus</arm_group_label>
    <arm_group_label>vancomycin resistent staphylococcus aureus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        critically ill patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intensive care patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Rasha Hamed</investigator_full_name>
    <investigator_title>lecturer of anaesthesia</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

